Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.22B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 2.17M
Average 2.73M
Balance Sheet
Inspect the capital base behind the business.
Assets
$343.32M
FY 2025 · Annual
+114.1% YoYLiabilities
$96.38M
FY 2025 · Annual
+8.5% YoYEquity
$246.94M
FY 2025 · Annual
+245.2% YoYBalance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 149.1M | 87.88M | 143.94M | 139.04M | 319.77M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 6.63M | 1.19M | 3.42M | 892K | 1.45M |
| Total Current Assets | 159.6M | 96.42M | 149.87M | 142.13M | 324.65M |
| Property, Plant & Equipment (Net) | 50.61M | 25.91M | 20.41M | 15.87M | 16.18M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 2.64M | 0 | 0 | 0 | 2.32M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.11M | 3.95M | 2.46M | 2.37M | 183K |
| Total Non-current Assets | 54.35M | 29.86M | 22.86M | 18.23M | 18.67M |
| Total Assets | 213.96M | 126.28M | 172.73M | 160.36M | 343.32M |
| Account Payables | 21.76M | 10.95M | 6.37M | 3.59M | 6.28M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 33.56M | 18.11M | 9.77M | 0 |
| Other Current Liabilities | 4.14M | 4.63M | 4.99M | 6.43M | 10.85M |
| Total Current Liabilities | 51.75M | 62.79M | 36.76M | 26.23M | 26.55M |
| Long-term Debt | 37.19M | 37.97M | 40.51M | 43.94M | 18.17M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 3.74M | 4.13M | 1.58M | 1.31M | 51.66M |
| Total Non-current Liabilities | 66.83M | 62.54M | 61.04M | 62.61M | 69.83M |
| Total Liabilities | 118.57M | 125.33M | 97.79M | 88.84M | 96.38M |
| Common Stock | 0 | 1K | 2K | 2K | 3K |
| Retained Earnings | (235.65M) | (401.44M) | (513.01M) | (602.31M) | (711.3M) |
| Accumulated OCI | 0 | 0 | 0 | (4.03M) | (192K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 95.38M | 949K | 74.94M | 71.53M | 246.94M |
| Total Debt | 63.09M | 59.93M | 61.11M | 63.18M | 18.17M |
| Net Debt | (86.01M) | (27.95M) | (82.83M) | (75.86M) | (301.6M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $455.4M |
| Other Current | $6.0M |
| Total Current Assets | $461.4M |
| PP&E (Net) | $8.7M |
| Other Non-current | $270.0K |
| Total Non-current Assets | $9.0M |
| Total Assets | $470.4M |
Analysis
Selected assets total $470.4M for Latest. The largest visible component is Cash & Equivalents at $455.4M, about 96.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 | |
| 10-Q | Quarterly report | Aug 11, 2026 |
How much cash does TSHA have?
Taysha Gene Therapies, Inc. (TSHA) reported $319.77M in cash and equivalents in fiscal 2025.
How much debt does TSHA carry?
Taysha Gene Therapies, Inc. (TSHA) reported $18.17M of total debt, with net debt of -$301.60M.
Continue the stock analysis
Jump to another research area for this company.